BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Curaxys, New Spanish Biopharmaceutical Company Pioneer On Biopharmaceuticals Biosimilars


10/26/2009 12:03:11 PM

Cadiz Spain -- Curaxys is a biotechnology company that researches, develops, produces and marketing biosimilars products using new biotechnology process and offering to the market, high quality product at reasonable prices for the diseases treatment.

Technologies:

It is remarkable to inform that in the last 20 years have demonstrated that the baculoviruses maintains a reputation for producing high yields of recombinant proteins in insect cells. Despite the difficulties of working with a virus in eukaryotic cells, the fact that posttranslational modifications such as glycosylation, fatty acid acylacion , disulfide bond formation, and phosphorylation are carried out very similar to the same process in mammalian cells, demonstrating the value of bacuviruses as expression vectors.

We offer a complete range of biopharmaceuticals biosimilars with structure, recombinant protein and monoclonal antibody. The products are focused to improve the quality of life of patient with new concept of product at reasonable cost in the field of the immunology, cancer treatment, multiple sclerosis, and virology.

The productscurrently in pharmaceutical developement are:

Recombinants proteins: 1. Insulin 2. Growth Hormone 3. Erythropoietin 4. Granulocyte Colony Stimulating Factor ( GCSF) Monoclonal Antibodies: 1. Rituximab

2. Trastuzumab The founder and CEO and of the company is Dr. Manuel Esteban, PhD, MSc, MBA,. He has over three decades of experience in pharmaceutical and biopharmaceutical research conducted at leading pharmaceutical companies such as Juste SAQF, Sanofi-Aventis, DSM Pharmaceuticals and Antibioticos (Montedison).

Dr. Esteban has held a variety of research management roles in projects related to cell and microorganism culture, technological development, as well as chemical, biochemical and enzymatic technologies. He is also a proven business manager with the ability to bring in new clients, to create new companies and to develop business opportunities.

Read at BioSpace.com

Curaxys
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES